Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GULLIVER-1: GB1211 in NASH
NCT04607655Phase 2Withdrawn
- Sponsor
- Galecto, Inc.
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selvigaltin in Nonalcoholic steatohepatitis (NASH), sponsored by Galecto, Inc.. Planned start Mar 2021; status: withdrawn.
02
Drugs
selvigaltin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04607655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607655.